BLK vs RCUS · P/E 27, rev $24.22B vs rev $258.0M
BlackRock Inc (BLK) versus Arcus Biosciences Inc (RCUS) — a side-by-side from cached financials, not a winner call.
BlackRock Inc (BLK) is a asset management company listed on NYSE. It is led by Larry Fink.
Arcus Biosciences Inc (RCUS) is a biotechnology company listed on US.
Latest reported BLK revenue for 2025-12-31 was $24.22B. Net income was $5.55B. Revenue was up 89.3% from 2024-12-31 to 2025-12-31. BLK currently screens at market cap $172.19B and trailing P/E 26.6.
Latest reported RCUS revenue for 2024-12-31 was $258.0M. Net income was -$283.0M. Revenue was up 120.5% from 2023-12-31 to 2024-12-31. RCUS currently screens at market cap $885.2M.
BLK currently screens at market cap $172.19B and trailing P/E 26.6. RCUS currently screens at market cap $885.2M.
Not investment advice. Open the BLK and RCUS stock pages for the full models.
Not investment advice.